Literature DB >> 18683898

Binge eating disorder pharmacotherapy clinical trails--who is left out?

Anna I Guerdjikova1, Susan L McElroy.   

Abstract

OBJECTIVE: This report examined the characteristics of subjects interested in binge eating disorder (BED) pharmacotherapy trails who were ineligible for participation.
METHODS: Data on 2685 potential subjects interested in participating in five different placebo-controlled monotherapy trails of BED were analysed.
RESULTS: Of the 2685 potential subjects, 1230 (45.8%) were ineligible because they did not meet entry criteria, 586 (21.8%) were eligible for participation, 531 (19.8%) were not interested in the study and 338 (12.6%) were not contacted. Among the 1230 ineligible candidates, 525 (42.7%) were taking exclusionary psychotropic medication, 305 (24.8%) did not meet specified BED criteria, 157 (12.7%) were out of the required age (n = 83) or weight (n = 74) range, 212 (17.2%) had prohibited medical (n = 78) or psychiatric (n = 134) disorders and 31 (2.5%) were participating in weight loss programmes. DISCUSSION: Given the complexity of BED, future pharmacotherapy studies should examine a broader range of subjects, including subjects with subthreshold forms of BED, those with comorbid disorders and elderly subjects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18683898     DOI: 10.1002/erv.884

Source DB:  PubMed          Journal:  Eur Eat Disord Rev        ISSN: 1072-4133


  6 in total

1.  Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as.

Authors:  Carlos M Grilo; Marney A White
Journal:  Behav Res Ther       Date:  2013-01-18

Review 2.  Therapeutic options for binge eating disorder.

Authors:  Carla E Ramacciotti; Elisabetta Coli; Donatella Marazziti; Cristina Segura-García; Francesca Brambilla; Armando Piccinni; Liliana Dell'osso
Journal:  Eat Weight Disord       Date:  2013-04-09       Impact factor: 4.652

3.  Pharmacological management of binge eating disorder: current and emerging treatment options.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Anne M O'Melia
Journal:  Ther Clin Risk Manag       Date:  2012-05-08       Impact factor: 2.423

4.  Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials.

Authors:  Michele Fornaro; Marco Solmi; Giampaolo Perna; Domenico De Berardis; Nicola Veronese; Laura Orsolini; Licinia Ganança; Brendon Stubbs
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-25       Impact factor: 2.570

5.  "Include me if you can"-reasons for low enrollment of pediatric patients in a psychopharmacological trial.

Authors:  Larissa Niemeyer; Konstantin Mechler; Jan Buitelaar; Sarah Durston; Bram Gooskens; Bob Oranje; Tobias Banaschewski; Ralf W Dittmann; Alexander Häge
Journal:  Trials       Date:  2021-03-01       Impact factor: 2.279

6.  The clinical significance of binge eating among older adult women: an investigation into health correlates, psychological wellbeing, and quality of life.

Authors:  Lisa Smith Kilpela; Victoria B Marshall; Pamela K Keel; Andrea Z LaCroix; Sara E Espinoza; Savannah C Hooper; Nicolas Musi
Journal:  J Eat Disord       Date:  2022-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.